| Name | Nexopamil racemate |
|---|---|
| Synonyms |
Benzeneacetonitrile, α-[3-(hexylmethylamino)propyl]-3,4,5-trimethoxy-α-(1-methylethyl)-
5-[Hexyl(methyl)amino]-2-isopropyl-2-(3,4,5-trimethoxyphenyl)pentanenitrile |
| Description | Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca2+/5-HT2 antagonist on thrombus formation in vivo and on platelet aggregation in vitro. |
|---|---|
| Related Catalog | |
| Target |
Ca2+/5-HT2[1] |
| In Vitro | Serotonin-induced platelet aggregation in dog platelet-rich plasma (PRP) in vitro is most potently inhibited by Nexopamil (IC50 81 nM) [1]. |
| In Vivo | Nexopamil (0.05 mg/kg) completely abolishes cyclic flow reductions (CFRs) during the first 30 min after application without significantly altering hemodynamics[1]. |
| References |
| Density | 1.0±0.1 g/cm3 |
|---|---|
| Boiling Point | 514.7±50.0 °C at 760 mmHg |
| Molecular Formula | C24H40N2O3 |
| Molecular Weight | 404.586 |
| Flash Point | 265.1±30.1 °C |
| Exact Mass | 404.303894 |
| LogP | 4.45 |
| Vapour Pressure | 0.0±1.3 mmHg at 25°C |
| Index of Refraction | 1.492 |